Clinuvel Pharmaceuticals

Rising Healthcare Expenditure And Aging Population Will Drive SCENESSE Uptake

AnalystHighTarget

Not Invested

Consensus Narrative from 7 Analysts

Published

16 Jul 25

AnalystHighTarget's Fair Value

AU$37.25

71.0% undervalued

05 Sep

AU$10.80

-26.7%

3.5%

-26.7%

3.5%

Edit anytime before Jul 16 9:12 PM. Then post Updates to your followers.

Author's Valuation

AU$37.3

71.0% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

AU$37.3

71.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

21.20%

Biotech revenue growth rate

7.59%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.48%

Calculation

AU$164.17m

Earnings '28

13.70x

PE Ratio '28

AU$2.25b

Market Cap '28

AU$2.25b

Market Cap '28

50.29m

No. shares '28

AU$44.71

Share Price '28

AU$44.71 Share Price '28

Discounted to 2025 @ 6.48% p.a.

AU$37.03

Fair Value '25